Plasma Protease C1-inhibitor Treatment Market Worth US$7.9 Billion by 2025, Globally: Transparency Market Research

Tuesday, October 24, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

Global Plasma Protease C1-inhibitor Treatment Market: Players Focus on Expanding Product Portfolio to Expand Outreach

ALBANY, New York, October 24, 2017 /PRNewswire/ --

According to estimations of the TMR report, the demand in

the global plasma protease c1-inhibitor treatment market will expand at a strong 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be evaluated at US$7.9 bn by 2025-end considerably up from its evaluated worth of US$1.5 bn in 2016. Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level.

View Full Report at https://www.transparencymarketresearch.com/plasma-protease-c1inhibitor-treatment-market.html

In terms of drug class, the global plasma protease C1-inhibitor treatment market witness maximum demand from the segment of c1-inhibitors that led amongst other segments in 2016. Geography-wise, the report assesses North America to be the most profitable market for plasma protease c1-inhibitor treatment, which accounted for a demand worth US$1,510.5 mn in 2017.

Hefty Investment for Innovation in Inhibitor Drugs Boosts Growth 

Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2025.

Request to View Sample Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33116  

One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults.

Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.

Apart from this, commercialization of drugs such as Ruconest in emerging markets of Asia Pacific is likely to boost the C1-inhibitor segment in the upcoming years.

Research studies underway for the development of bradykinin B2 receptor antagonist for the treatment of HAE attacks is likely to propel the global plasma protease C1-inhibitor treatment market. At present, Firazyr is the only approved bradykinin B2 receptor for the treatment of acute HAE attack.  FR 173657 is another bradykinin B2 receptor that researchers are evaluating for efficacy for acute HAE attack.

Request to download and view full ToC - https://www.transparencymarketresearch.com/report-toc/33116

A fresh market intelligence study by Transparency Market Research (TMR) states that the business landscape of the global plasma protease c1-inhibitor treatment market is consolidated with intense competitive rivalry among leading players. TMR detects Shire plc led the global plasma protease C1-inhibitor treatment market in 2016. Key factors that account for its dominance are expanded product portfolio, acquisitions, and widespread market presence. Pharming Group N.V., CSL Limited, and Sanquin are some other key vendors that hold significant shares in the overall market for plasma protease C1-inhibitor treatment.

Plasma Protease C1-inhibitor Treatment Market Research Report is available @ US$ 5795

About TMR 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Transparency Market Research State Tower 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected]

Website: http://www.transparencymarketresearch.com TMR Blog: http://www.theglobalhealthnews.com/

SOURCE Transparency Market Research



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store